NCT02520778 2024-08-21Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 1 Completed27 enrolled